Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Current Liabilities (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Total Current Liabilities for 14 consecutive years, with $166.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 17.98% to $166.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $166.1 million through Dec 2025, up 17.98% year-over-year, with the annual reading at $166.1 million for FY2025, 17.98% up from the prior year.
  • Total Current Liabilities hit $166.1 million in Q4 2025 for Corcept Therapeutics, down from $172.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $172.3 million in Q3 2025 to a low of $40.6 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $95.0 million across 5 years, with a median of $95.1 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: grew 0.1% in 2021 and later soared 129.65% in 2023.
  • Year by year, Total Current Liabilities stood at $47.5 million in 2021, then soared by 52.48% to $72.5 million in 2022, then surged by 44.16% to $104.5 million in 2023, then soared by 34.7% to $140.8 million in 2024, then grew by 17.98% to $166.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for CORT at $166.1 million in Q4 2025, $172.3 million in Q3 2025, and $144.7 million in Q2 2025.